Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
Department of Biochemistry and Molecular Biology II, School of Pharmacy, Complutense University of Madrid, and Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, IdISSC, Madrid, Spain.
Hepatology. 2016 Feb;63(2):604-19. doi: 10.1002/hep.28134. Epub 2015 Oct 10.
Different data support a role for the epidermal growth factor receptor (EGFR) pathway during liver regeneration and hepatocarcinogenesis. However, important issues, such as the precise mechanisms mediating its actions and the unique versus redundant functions, have not been fully defined. Here, we present a novel transgenic mouse model expressing a hepatocyte-specific truncated form of human EGFR, which acts as negative dominant mutant (ΔEGFR) and allows definition of its tyrosine kinase-dependent functions. Results indicate a critical role for EGFR catalytic activity during the early stages of liver regeneration. Thus, after two-thirds partial hepatectomy, ΔEGFR livers displayed lower and delayed proliferation and lower activation of proliferative signals, which correlated with overactivation of the transforming growth factor-β pathway. Altered regenerative response was associated with amplification of cytostatic effects of transforming growth factor-β through induction of cell cycle negative regulators. Interestingly, lipid synthesis was severely inhibited in ΔEGFR livers after partial hepatectomy, revealing a new function for EGFR kinase activity as a lipid metabolism regulator in regenerating hepatocytes. In spite of these profound alterations, ΔEGFR livers were able to recover liver mass by overactivating compensatory signals, such as c-Met. Our results also indicate that EGFR catalytic activity is critical in the early preneoplastic stages of the liver because ΔEGFR mice showed a delay in the appearance of diethyl-nitrosamine-induced tumors, which correlated with decreased proliferation and delay in the diethyl-nitrosamine-induced inflammatory process.
These studies demonstrate that EGFR catalytic activity is critical during the initial phases of both liver regeneration and carcinogenesis and provide key mechanistic insights into how this kinase acts to regulate liver pathophysiology. (Hepatology 2016;63:604-619).
不同的数据支持表皮生长因子受体(EGFR)途径在肝再生和肝癌发生中的作用。然而,一些重要的问题,如介导其作用的精确机制及其独特的与冗余的功能,尚未得到充分的定义。在这里,我们提出了一种新的转基因小鼠模型,表达一种肝细胞特异性的人 EGFR 截断形式,其作为负显性突变体(ΔEGFR),并允许定义其酪氨酸激酶依赖的功能。结果表明,EGFR 催化活性在肝再生的早期阶段起着关键作用。因此,在三分之二的部分肝切除术后,ΔEGFR 肝脏显示出较低和延迟的增殖以及较低的增殖信号激活,这与转化生长因子-β途径的过度激活相关。改变的再生反应与细胞周期负调节剂的诱导有关,通过诱导细胞周期负调节剂放大转化生长因子-β的细胞静止作用。有趣的是,部分肝切除术后ΔEGFR 肝脏的脂质合成受到严重抑制,揭示了 EGFR 激酶活性作为再生肝细胞中脂质代谢调节剂的新功能。尽管有这些深刻的改变,ΔEGFR 肝脏能够通过过度激活补偿信号(如 c-Met)来恢复肝质量。我们的研究结果还表明,EGFR 催化活性在肝的早期癌前阶段是至关重要的,因为ΔEGFR 小鼠显示出二乙基亚硝胺诱导的肿瘤出现延迟,这与增殖减少和二乙基亚硝胺诱导的炎症过程延迟相关。
这些研究表明,EGFR 催化活性在肝再生和癌发生的初始阶段都是至关重要的,并为该激酶如何调节肝病理生理学提供了关键的机制见解。(《肝脏病学》2016;63:604-619)。